Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 22889054)

1.

Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study.

Bennis S, Abbass F, Akasbi Y, Znati K, Joutei KA, El Mesbahi O, Amarti A.

BMC Res Notes. 2012 Aug 13;5:436. doi: 10.1186/1756-0500-5-436.

2.

Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco.

El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A.

Diagn Pathol. 2012 Dec 7;7:170. doi: 10.1186/1746-1596-7-170. Retraction in: Diagn Pathol. 2013;8:127.

3.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
4.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
5.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
6.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

7.

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.

Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z.

Cancer Sci. 2012 Sep;103(9):1679-87. doi: 10.1111/j.1349-7006.2012.02339.x. Epub 2012 Jul 4.

8.

Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.

Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup SP, León M, de la Cruz MA, Vigil CE.

Clin Breast Cancer. 2010 Aug 1;10(4):294-300. doi: 10.3816/CBC.2010.n.038.

PMID:
20705562
9.

Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.

Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.

PMID:
23040002
10.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26.

PMID:
19034706
11.

MMP-1 expression has an independent prognostic value in breast cancer.

Boström P, Söderström M, Vahlberg T, Söderström KO, Roberts PJ, Carpén O, Hirsimäki P.

BMC Cancer. 2011 Aug 11;11:348. doi: 10.1186/1471-2407-11-348.

12.

Pathological features and prognosis of different molecular subtypes of breast cancer.

Wang GS, Zhu H, Bi SJ.

Mol Med Rep. 2012 Oct;6(4):779-82. doi: 10.3892/mmr.2012.981. Epub 2012 Jul 9.

PMID:
22797840
13.

Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez).

Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA, Amarti A, Mesbahi OE.

BMC Res Notes. 2011 Nov 16;4:500. doi: 10.1186/1756-0500-4-500.

14.

Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes.

Kim J, Lee S, Bae S, Choi MY, Lee J, Jung SP, Kim S, Choe JH, Kim JH, Kim JS, Lee JE, Nam SJ, Yang JH.

Breast Cancer Res Treat. 2012 Jan;131(2):527-40. doi: 10.1007/s10549-011-1836-0. Epub 2011 Oct 30.

PMID:
22042364
15.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481
16.

Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.

Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H, Errihani H.

BMC Womens Health. 2012 Oct 7;12:35. doi: 10.1186/1472-6874-12-35.

17.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

18.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.

J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

19.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
20.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk